Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.

Authors
Category Primary study
JournalJAMA neurology
Year 2022
This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.
Epistemonikos ID: 91148e88ee99d89c90be0cc1d9dac49c2554fcbc
First added on: Jan 26, 2022